EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, presented several notable studies. Among them, three studies—B254, B259, and A001—focused on comprehensive leukemia management and transplant integration, drawing significant attention from the clinical community. Hematology Frontier invited Prof. Xiaoxia Hu to provide in-depth commentary on these research findings.
EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation

EBMT 2025 | Prof. Qifa Liu: Emerging Strategies for GVHD Prevention—Mesenchymal Stem Cells and Fecal Microbiota Transplantation

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in the historic city of Florence, Italy. As one of the most influential global events in the field of hematology, the Annual Meeting gathered over 5,000 experts and scholars from around the world to explore cutting-edge advances in hematopoietic stem cell transplantation (HSCT) and cellular therapy.At the Annual Meeting , Hematology frontier had the honor of speaking with Professor Qifa Liu of the Nanfang Hospital, Southern Medical University. Prof. Liu shared his insights on the latest progress in graft-versus-host disease (GVHD) prevention and treatment, particularly focusing on the innovative applications of mesenchymal stem cells (MSCs) and fecal microbiota transplantation (FMT). He also reflected on the impact of this year’s Annual Meeting on ongoing and future clinical research directions.
EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML

EBMT 2025 | Prof. Erlie Jiang & Dr. Mingyang Wang: Using CBFB-MYH11 Fusion Transcript Ratios to Guide Transplant Timing in Low-Risk AML

Hematopoietic stem cell transplantation (HSCT) remains a curative treatment for numerous hematologic disorders. Despite its life-saving potential, many clinical challenges persist, particularly concerning patient selection, transplant timing, and long-term management. To enhance academic exchange and practical insights in the field of transplantation, Hematology Frontier launched the special feature "Transplantation Pathways Spotlight" during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). This column brings together leading experts from China and abroad to discuss full-cycle transplant care, from pre-transplant assessment through to long-term recovery, aiming to establish an integrated and forward-looking framework for clinical transplantation.
EBMT 2025| Prof. He Huang: A Transplant-CAR-T-Nursing Triad Unleashes New Momentum in Hematology

EBMT 2025| Prof. He Huang: A Transplant-CAR-T-Nursing Triad Unleashes New Momentum in Hematology

Hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for hematologic diseases. However, despite its curative potential, many clinical challenges persist. To promote academic exchange and practical innovation in the field of transplantation, Hematology Frontier launched the “Transplantation Pathways Spotlight” during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). This column invites renowned transplantation teams from China and abroad to focus on full-cycle transplant care—from precise pre-transplant assessment to long-term post-transplant recovery—building a comprehensive, integrated transplant management framework.
EAU 2025 | Dr. Ashwin Sachdeva: ADT Therapy for mHSPC Upgraded—Combination with Metformin Improves Survival in High-Volume Patients and Reduces Metabolic Syndrome Risk

EAU 2025 | Dr. Ashwin Sachdeva: ADT Therapy for mHSPC Upgraded—Combination with Metformin Improves Survival in High-Volume Patients and Reduces Metabolic Syndrome Risk

Currently, ADT remains the cornerstone treatment regimen for mHSPC. However, long-term use of ADT may increase the risk of cardiovascular events. Recently, the data from the STAMPEDE study presented at the European Association of Urology (EAU) Congress showed that the combination of metformin and ADT can extend the overall survival of patients with high tumor burden mHSPC by 10 months (hazard ratio [HR] = 0.79). At the same time, it can also improve metabolic indicators: there is less weight gain (2.5 kg vs 4 kg) and a lower incidence of metabolic syndrome (4.9% vs 9.4%). UroStream specially invited the study presenter, Dr. Ashwin Sachdeva, a senior clinical lecturer in University of Manchester, Division of Cancer Sciences, to share the wonderful content on-site.
EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive Cancer Center shared key insights on the response of different bladder cancer types to treatment, the role of neoadjuvant therapy, and the growing possibilities of bladder-sparing strategies.
EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

EAU 2025丨Dr. Siamak Daneshmand Shares the Potential of Oncolytic Virus Therapy for NMIBC Patients

For patients with non-muscle-invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) therapy, clinicians and researchers are actively exploring novel treatment strategies. Among these, oncolytic virus therapy has emerged as a promising approach. At the 40th Annual EAU Congress, Dr. Siamak Daneshmand from the University of Southern California (USC) presented two key studies on oncolytic viruses—the BOND-003 P cohort and the PIVOT-006 trial. UroStream invited Professor Daneshmand to discuss the mechanism of action, safety, efficacy, and future directions of this innovative therapy.
EAU 2025 | Non-Invasive Evaluation of Tumor Heterogeneity in BCR: Professor Xuefeng Qiu Shares Advancements and Clinical Experience with PSMA-PET/CT at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University

EAU 2025 | Non-Invasive Evaluation of Tumor Heterogeneity in BCR: Professor Xuefeng Qiu Shares Advancements and Clinical Experience with PSMA-PET/CT at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University

In recent years, prostate-specific membrane antigen (PSMA) molecular imaging technology has demonstrated significant value in the diagnosis and treatment of prostate cancer. It has improved the accuracy of clinical staging, supported multimodal treatment decision-making, and facilitated the development of precision medicine through novel radioligand therapies. At the recent EAU Congress, UroStream invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, to share insights into his team’s research on PSMA PET/CT for predicting biochemical recurrence (BCR), the impact of tumor heterogeneity, and the clinical experience at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University.
Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

The St. Gallen International Breast Cancer Conference (SGBCC) is one of the most authoritative and influential global events in the field of breast cancer, dedicated to advancing standardized diagnosis and treatment for early-stage breast cancer. To integrate international frontier concepts with domestic clinical practice and align China’s breast cancer care with global standards—ultimately delivering superior treatment options for patients—Professor Michael Gnant, President of SGBCC, visited The Second Hospital of Dalian Medical University on April 9 for a two-day academic exchange and collaboration initiative.